Search PubMed⌕ Search

Biomedical subjects

J M Land

Publications and source records attributed to J M Land.

77 records · Page 5Linked to original sources

Effect of phenylpyruvate on pyruvate dehydrogenase activity in rat brain mitochondria.

1. The effects of phenylpyruvate, a metabolite produced in phenylketonuria, on the pyruvate dehydrogenase-complex activity were investigated in rat brain mitochondria. 2. Pyruvate dehydrogenase activity was measured by two methods, one measuring the release of (14)CO(2) from [1-(14)C]pyruvate and the other measuring the acetyl-CoA formed by means of the coupling enzyme, pigeon liver arylamine acetyltransferase (EC 2.3.1.5). In neither case was there significant inhibition of the pyruvate dehydrogenase complex by phenylpyruvate at concentrations below 2mm. 3. However, phenylpyruvate acted as a classical competitive inhibitor of the coupling enzyme arylamine acetyltransferase, with a K(i) of 100mum. 4. It was concluded that the inhibition of pyruvate dehydrogenase by phenylpyruvate is unlikely to be a primary enzyme defect in phenylketonuria.

Journal Article↗

Effect of phenylpyruvate on enzymes involved in fatty acid synthesis in rat brain.

1. The activities of, and the effects of phenylpyruvate on, citrate synthase (EC 4.1.3.7), acetyl-CoA carboxylase (EC 6.4.1.2) and fatty acid synthetase derived from the brains of 14-day-old and adult rats were investigated. 2. The brain citrate synthase from 14-day-old rats had a K(m) for oxaloacetate of 2.38mum and for acetyl-CoA of 16.9mum, and a V(max.) of 838nmol of acetyl-CoA incorporation/min per mg of mitochondrial protein. From adult rat brain this enzyme had a K(m) for oxaloacetate of 2.5mum and for acetyl-CoA of 16.6mum and a V(max.) of 1070nmol of acetyl-CoA incorporated/min per mg of mitochondrial protein. Phenylpyruvate inhibited the enzyme from adult and young rat brains in a competitive fashion with respect to acetyl-CoA, with a K(i) of 700mum. 3. The brain acetyl-CoA carboxylase from 14-day-old rats had a K(m) for acetyl-CoA of 21mum and a V(max.) of 0.248nmol/min per mg of protein, and from adult rats a K(m) for acetyl-CoA of 21mum and a V(max.) of 0.173nmol/min per mg of protein. The enzyme from young and adult rats required citrate (K(a)=3mm) for activation and were inhibited non-competitively by phenylpyruvate, with a K(i) of 10mm. 4. The brain fatty acid synthetase from 14-day-old rats had a K(m) for acetyl-CoA of 7.58mum and a V(max.) of 1.1 nmol of malonyl-CoA incorporated/min per mg of protein, and from adult rats a K(m) for acetyl-CoA of 4.9mum and a V(max.) of 0.48nmol of malonyl-CoA incorporated/min per mg of protein. Phenylpyruvate acted as a competitive inhibitor with respect to acetyl-CoA with a K(i) of 250mum for the enzyme from 14-day-old rats. 5. These results are discussed with respect to phenylketonuria, and it is suggested that the inhibition of the brain fatty acid synthetase and possibly the citrate synthetase by phenylpyruvate could explain the defective myelination characteristic of this condition.

Journal Article↗

PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.

14 untreated patients with Hodgkin's disease were tested for lymphocte reactivity in vitro to optimal and suboptimal doses of PHA. A PHA dose-dependent defect in lymphocyte stimulation was demonstrated in patients when compared with a group of normal individuals. No correlation between the in vitro defect and decreased absolute number of E-rosette-forming cells (T-lymphocytes) in peripheral blood was found.

Adolescent↗